Daily non-political popular news in brief.
Prostate cancer therapy may increase risk of death from heart disease in older men
02-24-2007 · EurekAlert!Androgen deprivation therapy -- one of the most common treatments for prostate cancer -- may increase the risk of death from heart disease in patients over age 65, according to a new study by researchers at Dana-Farber Cancer Institute, Brigham and Women's Hospital and other institutions.
Read more »
Keywords: prostate, cancer, therapy, risk, death, heart, disease, older, men
« Previous | Next »
Similar news on "Prostate cancer therapy may increase risk of death from heart disease in older men":
- Prostate cancer therapy linked to increased risk of heart disease death
10-09-2007 · EurekAlert!
The use of androgen deprivation therapy to treat localized prostate cancer is associated with an increased risk of death from heart disease, according to a study published online Oct. 9 in the Journal of the National Cancer Institute.
Similar news · Read more »
- Analysis: Older men treated for early prostate cancer
12-12-2006 · EurekAlert!
An analysis of Surveillance, Epidemiology and End Results-Medicare records for 44,630 older men suggests surgery or radiation therapy for early-stage prostate cancer increased the lifespan of men between 65 and 80 years old compared to observation, sometimes known as "watch and wait." The study supported a benefit of treatment even for men whose disease had a low risk of spreading, and even if they were elderly men (75 to 80 years old).
Similar news · Read more »
- Analysis: Older men treated for early prostate cancer live longer than those not treated
12-12-2006 · EurekAlert!
An analysis of Surveillance, Epidemiology and End Results-Medicare records for 44,630 older men suggests surgery or radiation therapy for early-stage prostate cancer increased the lifespan of men between 65 and 80 years old compared to observation, sometimes known as "watch and wait." The study supported a benefit of treatment even for men whose disease had a low risk of spreading, and even if they were elderly men (75 to 80 years old).
Similar news · Read more »
- Just 4 months of hormone therapy can delay prostate cancer growth by up to 8 years
01-02-2008 · EurekAlert!
Researchers report that just four months of hormonal therapy before and with standard external beam radiation therapy slowed cancer growth by as much as eight years -- especially the development of bone metastases -- and increased survival in older men with potentially aggressive prostate cancer. This "neoadjuvant" hormonal therapy may allow men most at risk of developing bone metastases avoid long-term hormonal therapy later on.
Similar news · Read more »
- Adding radiation therapy for treatment of advanced prostate cancer may offer benefit
11-14-2006 · EurekAlert!
Treating advanced prostate cancer with radiation therapy after removal of the prostate gland reduces the risk of disease recurrence, but does not appear to significantly improve the length of survival, according to a study in the Nov. 15 issue of JAMA, a theme issue on men's health.
Similar news · Read more »
- Height loss in older men associated with increased risk of heart disease, death
12-11-2006 · EurekAlert!
Men who lose three centimeters or more of height as they age have an increased risk of death and of coronary heart diseases events, according to a report in the December 11/25 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Similar news · Read more »
- Radiation after surgery keeps high-risk prostate cancer at bay
10-30-2007 · EurekAlert!
An analysis of data involving more than 2,000 patients from 17 US institutions demonstrates that men with high-risk prostate cancer who receive radiation therapy after a prostatectomy were less likely to have a recurrence of disease. What's more, men whose cancer persists after surgery were less likely to see the cancer spread if they receive radiation.
Similar news · Read more »
- PSA doubling predicts prostate cancer recurrence
04-09-2007 · EurekAlert!
A detectable level of prostate-specific antigen (PSA) is the first indicator of recurrent prostate cancer after radical prostatectomy. In a new Mayo Clinic study, the concept of PSA doubling time is found to be a reliable tool to distinguish which patients have prolonged innocuous PSA levels after therapy from those who are at great risk for disease recurrence and death from prostate cancer. Doubling time is defined as the duration for PSA levels in the blood to increase by 100 percent.
Similar news · Read more »
- Phase II study shows HRPC patients with bone metastases see improved survival with ZD4054
09-25-2007 · EurekAlert!
New Phase II data presented today suggest that ZD4054, a novel compound in development for the treatment of men with hormone-resistant prostate cancer, could offer a promising improvement in overall survival in men with metastatic HRPC who were asymptomatic or mildly symptomatic for pain.1 Patients who received ZD4054 10mg once-daily experienced a 45 percent reduction in the risk of death compared to placebo.
Similar news · Read more »
- Fatherhood linked to prostate cancer risk
01-07-2008 · EurekAlert!
A new study from Danish researchers has found that childless men have a lower risk of developing prostate cancer than fathers, and that, paradoxically, the more children a father has, the lower the risk of the disease.
Similar news · Read more »
